Home·Stocks·QURE
uniQure N.V.

QURE

XNAS

uniQure N.V.

Basic Materials · Pharmaceutical Preparations

$28.45
+3.60 (+14.49%)
15-min delayed

Drag to pan · Scroll to zoom · Hover for OHLC

Snapshot
Loading metrics…
About uniQure N.V.

uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases. Its program and pipeline involves: Huntington's Disease, Temporal Lobe Epilepsy (TLE), Fabry Disease, ALS (SOD1), Hemophilia B, Clinical Trials, and Research Programs.

Employees
221
Country
US
IPO Date
2014-02-05
www.uniqure.com
COMMUNITY · $QURE0 theses
POST YOUR TAKE →
Analyst Ratings
Loading…
Financials
Loading SEC filings…
Insider Activity
Loading filings…
Related Stocks
Loading peers…

Data is 15-minute delayed, for informational purposes only. Not investment advice. Prices via Massive.com consolidated feed. Fundamentals via FinancialModelingPrep. News via Finnhub.

QURE uniQure N.V. Stock — $28.45 +14.49% · AlgoThesis